Last update 08 Jun 2026

Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.

Subsidiary Company|2021|Shanghai Shi, China

Overview

Tags

Nervous System Diseases
Other Diseases
Small molecule drug
Antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases5
Top 5 Drug TypeCount
Small molecule drug3
Antibody2
Top 5 TargetCount
NMDA receptor(Glutamate [NMDA] receptor)3
APOE(Apolipoprotein E)2

Related

5
Drugs associated with Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
SP-101(Synphatec)
Target
NMDA receptor
Mechanism
NMDA receptor antagonists
Active Org.
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Originator Org.
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Active Indication
Depressive Disorder, Major [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
SP-102 (Synphatec)
Target
NMDA receptor
Mechanism
NMDA receptor antagonists
Active Org.
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Originator Org.
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Active Indication
Depressive Disorder [+1]
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
SP-201 (Synphatec)
Target
APOE
Mechanism
APOE antagonists
Active Org.
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Originator Org.
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Active Indication
Alzheimer Disease
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
NCT07334249
/ Not yet recruitingPhase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SP-101 Injection Following Single and Multiple Intravenous Doses in Healthy Adult Subjects
100 Clinical Results associated with Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Login to view more data
100 Deals associated with Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
4
1
Phase 1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free